Overall, all evaluated BTKi-BCL2-antiCD20 triplets demonstrate efficacy in short follow-up for unselected patients with CLL and those with TP53 aberrancy. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.